On January 29, 2018 Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, reported that it will host a Key Opinion Leader (KOL) Event in New York on Tuesday, February 6th from 8-10:30 AM EDT (Press release, Pieris Pharmaceuticals, JAN 29, 2018, View Source [SID1234523614]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The KOL event will feature world-class thought leaders in immuno-oncology and respiratory diseases, followed by a company presentation. The event will include presentations from:
Michael A. Curran, PhD, Assistant Professor in the Department of Immunology and Scientific Director of the Oncology Research for Biologics and Immunotherapy Translation (ORBIT) platform at MD Anderson Cancer Center.
David H. Ilson, MD PhD, Medical Oncologist and Attending Physician at Memorial Sloan Kettering Cancer Center and Professor at Weill Cornell Medical College.
Gary Anderson, PhD, FThorSoc, FERS, Professor in the Medical Faculty at the University of Melbourne and Director of the Centre for Lung Health Research.
Bruce Levy, MD, Parker B. Francis Professor of Medicine at Brigham and Women’s Hospital and the Chief of the Pulmonary and Critical Care Division.
The event will be accessible via a live webcast through this link beginning at 8am on February 6th.
In-person attendance is by invitation only. For more information please contact Clayton Robertson at [email protected].